LB Pharmaceuticals
LB Pharmaceuticals

LBRX - LB Pharmaceuticals • Financials

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2022
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2023
0
-11
-1
0%
L
-34
L
-43
-
-12
-0
34
-12
0
0
-
-
12/2024
0
-65
-12
0%
L
-95
L
-28
-
-56
-1
38
-57
0
0
-
-
12/2025
0
-30
-12
0%
L
301
L
-295
-
-39
-0
303
-39
0
0
-
-

To see all financials—including updated, you must be Premium.